加拿大、澳大利亚、新西兰和美国原住民中的癫痫:一项系统范围综述
该研究系统检索1985年1月1日至2023年4月16日发表的文献,纳入42篇同行评议文章和9篇灰色文献报告,覆盖加拿大、澳大利亚、新西兰和美国原住民的癫痫数据。除新西兰毛利儿童外,原住民癫痫发病率和患病率似乎高于非原住民;原住民癫痫住院次数更多、专科就诊机会更少、抗癫痫药物可及性更差且等待时间更长、酶诱导型抗癫痫药物处方更多;澳大利亚原住民癫痫伤残调整生命年是非原住民的两倍,新西兰和澳大利亚原住民癫痫死亡率高于非原住民。
要点
- 研究纳入42篇同行评议文章和9篇灰色文献报告,涉及加拿大3项、澳大利亚17项、新西兰9项、美国22项。
- 除新西兰毛利儿童外,原住民癫痫发病率和患病率似乎高于非原住民人群。
- 澳大利亚原住民癫痫伤残调整生命年是非原住民的两倍,新西兰和澳大利亚原住民癫痫死亡率更高。
核心结论
- 尽管加拿大、澳大利亚、新西兰和美国原住民文化身份独特,本综述发现原住民与非原住民之间存在相似主题和显著差异。
- 相关研究相对较少且质量参差不齐,存在大量知识空白;亟需针对各国特定原住民群体开展癫痫流行病学研究以支持卫生政策制定并减少不公平。
研究设计与样本
- 系统范围综述,检索Embase、MEDLINE、APA PsychInfo、Cochrane、Scopus、CINAHL数据库及灰色文献,纳入1985年1月1日至2023年4月16日以任何语言发表的报告。
- 由三名评审员独立评估,纳入包含原住民群体癫痫数据的文章,排除将原住民与非原住民合并为一个人群或未按原住民群体单独分析结局的文章,并排除病例报告。
- 共检索到2037项研究,最终纳入42篇同行评议文章和9篇灰色文献报告:加拿大3项、澳大利亚17项、新西兰9项、美国22项。
主要发现
- 除新西兰毛利儿童外(其癫痫发生率似乎与欧洲血统儿童相似),原住民癫痫发病率和患病率似乎高于非原住民人群。
- 原住民癫痫住院次数更多、专科就诊机会更少、抗癫痫药物可及性更差且等待时间更长、酶诱导型抗癫痫药物处方更多。
- 澳大利亚原住民和托雷斯海峡岛民癫痫患者的伤残调整生命年是非原住民癫痫患者的两倍。
- 新西兰和澳大利亚原住民癫痫患者死亡率高于非原住民癫痫患者。
关键数值与推荐
- 纳入标准:包含原住民群体癫痫数据的文章;排除标准:将原住民与非原住民合并为一个人群或未按原住民群体单独分析结局的文章,以及病例报告。
- 采用方法学评价和原住民视角评价评估研究方法学质量。
- 研究注册于Open Science Framework,注册号https://doi.org/10.17605/OSF.IO/9JRHG。
临床怎么用
- 原文未据此给出推荐。
局限性
- 相关研究相对较少且质量参差不齐,存在大量知识空白。
- 亟需针对加拿大、澳大利亚、新西兰和美国各国特定原住民群体开展癫痫流行病学研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Indigenous peoples have inequitable health access and outcomes yet are under-represented in health research and policy. The Intersectoral Global Action Plan on Epilepsy and other Neurological Disorders 2022-2031 highlights Indigenous peoples as high priority groups. We aimed to provide a summary of existing knowledge regarding epilepsy among Indigenous peoples in Canada, Australia, New Zealand, and the USA (CANZUS). METHODS: In this systematic scoping review, we searched Embase, MEDLINE, APA PsychInfo, Cochrane, Scopus, CINAHL databases and grey literature for reports published in any language between Jan 1, 1985, and April 16, 2023, using search terms related to seizures, epilepsy, and Indigenous peoples. Studies were assessed independently by three reviewers. Articles including epilepsy data in an Indigenous group were included. Articles were excluded if they combined Indigenous and non-Indigenous peoples as one population or if the outcomes did not include a separate analysis by Indigenous group. Case reports were also excluded. We extracted data on epilepsy epidemiology, access to health care, treatment, and health outcomes in Indigenous people. The methodological quality of studies was assessed through a methodological appraisal and an Indigenous perspective appraisal. This study is registered with Open Science Framework, https://doi.org/10.17605/OSF.IO/9JRHG. FINDINGS: Our search identified 2037 studies, of which 42 peer-reviewed articles and nine grey literature reports met inclusion criteria: these studies were in Canada (n=3), Australia (n=17), New Zealand (n=9), and the USA (n=22). With the exception of Māori children in New Zealand, who seem to have similar rates of epilepsy to children of European ancestry, the incidence and prevalence of epilepsy seemed to be higher in Indigenous peoples in these regions than non-Indigenous populations. In the included studies, Indigenous peoples showed a higher number of epilepsy hospital presentations, decreased access to specialists, decreased access and longer waits for antiseizure medication, and increased prescriptions for enzyme-inducing antiseizure medications when compared with non-Indigenous peoples. In Australia, the number of disability-adjusted life years among Aboriginal and Torres Strait Islander peoples with epilepsy was double that for non-Indigenous people with epilepsy. Mortality rates for Indigenous peoples with epilepsy in New Zealand and Australia were higher than in non-Indigenous people with epilepsy. INTERPRETATION: Although Indigenous people from CANZUS have unique cultural identities, this review identified similar themes and substantial disparities experienced by Indigenous versus non-Indigenous people in these nations. Concerningly, there were relatively few studies, and these were of variable quality, leaving substantial knowledge gaps. Epidemiological epilepsy research in each specific Indigenous group from CANZUS countries is urgently required to enable health policy development and minimise inequity within these countries. FUNDING: Health Research Council of New Zealand.
引用
- Keenan NF, Aitchison SG, Jetté N, et al. Epilepsy in the Indigenous peoples in Canada, Australia, New Zealand, and the USA: a systematic scoping review. Lancet Glob Health. 2025. PMID: 40155103. doi:10.1016/S2214-109X(24)00507-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。